Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484766 | PMC |
| http://dx.doi.org/10.2169/internalmedicine.1282-22 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antibiotic Susceptibility-Guided Concomitant Therapy Regimen with Vonoprazan, High-Dose Amoxicillin, Clarithromycin, and Metronidazole for Eradication as Fourth-Line Regimen: An Interventional Study.
Microorganisms
October 2024
Department of Gastroenterology, Graduate School of Medicine, Yokohama City University, Yokohama 236-0004, Japan.
Article Synopsis
- * Twenty patients who had failed previous eradication therapies participated in the study, and the treatment lasted for 14 days, which was adjusted by removing any resistant drugs identified in prior tests.
- * The resulting eradication rates were 63.2% in overall analysis and 70.6% when strictly adhering to the protocol, suggesting this modified therapy could be an effective option after other treatments have failed, with no serious side effects reported.
Newer Therapies for Refractory Infection in Adults: A Systematic Review.
Antibiotics (Basel)
October 2024
Institute of Therapeutic Innovations and Outcomes (ITIO), College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
Background: () infection is a global health concern, affecting approximately two-thirds of the world's population. Standard first-line treatment regimens often fail, necessitating alternative rescue therapies.
Objectives: This review aims to evaluate the efficacy and safety of newer treatment regimens in patients who have failed initial eradication therapy.
Article Synopsis
- - This study aimed to compare the effectiveness of two first-line treatments for Helicobacter pylori eradication: a triple therapy featuring vonoprazan, amoxicillin, and metronidazole (VAM) versus another using vonoprazan, amoxicillin, and clarithromycin (VAC).
- - Conducted in Japan with 124 participants, the trial showed that both treatments yielded similar success rates for eradication, around 91% for VAM and 89% for VAC, without significant differences between them.
- - The results indicate that VAM can be considered an effective first-line treatment and suggests its classification as a grade B regimen, indicating a good potential for national insurance approval in Japan.
Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial).
Sci Rep
April 2024
Department of Medicine, Faculty of Medicine, Center of Excellence in Digestive Diseases and Gastroenterology Unit, Thammasat University, Pathum Thani, 12120, Thailand.
Potassium-competitive acid blockers (P-CABs) provide potent acid inhibition, yet studies on P-CAB-based quadruple therapy for H. pylori eradication are limited. We theorized that integrating bismuth subsalicylate into a quadruple therapy regimen could enhance eradication rates.
View Article and Find Full Text PDFProspective Study of Vonoprazan-Based First-Line Triple Therapy with Amoxicillin and Metronidazole for Clarithromycin-Resistant .
J Clin Med
August 2023
Department of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.
Aim: This was a prospective, multicenter, single-arm intervention, against historical controls, study of the efficacy of a vonoprazan-based 7-day triple regimen with metronidazole (VPZ-AMPC-MNZ) as a first-line therapy for eradicating clarithromycin-resistant ().
Methods: We enrolled 35 patients positive for clarithromycin-resistant , as assessed by culture, without a history of eradication. These 35 patients were prospectively eradicated with VPZ-AMPC-MNZ.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!